索拉菲尼-话题@MedSci

#索拉菲尼#

12篇内容 | 1493人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1344636, encodeId=2e0913446363e, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=Lancet oncol：AML移植后采用索拉菲尼维持治疗的疗效和耐受性, objectType=article, longId=199228, objectId=6fe419922898, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fe419922898, replyNumber=0, likeNumber=78, createdTime=2020-08-13, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fe419922898, moduleTitle=Lancet oncol：AML移植后采用索拉菲尼维持治疗的疗效和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fe419922898)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344635, encodeId=a82a134463566, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=JITC：中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制, objectType=article, longId=193417, objectId=b9b319341e19, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9b319341e19, replyNumber=0, likeNumber=74, createdTime=2020-05-04, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9b319341e19, moduleTitle=JITC：中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9b319341e19)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344634, encodeId=1bc3134463482, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=J Immunother Cancer：营养与健康所等揭示中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制, objectType=article, longId=191141, objectId=07ec191141e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07ec191141e3, replyNumber=0, likeNumber=98, createdTime=2020-04-01, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07ec191141e3, moduleTitle=J Immunother Cancer：营养与健康所等揭示中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07ec191141e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344633, encodeId=35c11344633cd, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=CLIN CANCER RES：索拉菲尼联合改良FOLFOX治疗晚期肝细胞癌, objectType=article, longId=158547, objectId=c8d615854e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8d615854e0d, replyNumber=0, likeNumber=76, createdTime=2019-01-22, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8d615854e0d, moduleTitle=CLIN CANCER RES：索拉菲尼联合改良FOLFOX治疗晚期肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8d615854e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344632, encodeId=b6f51344632d9, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=JAMA Oncol：大血管侵犯的晚期肝细胞癌：TACE+RT vs索拉菲尼, objectType=article, longId=144713, objectId=5e6f144e13a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e6f144e13a6, replyNumber=0, likeNumber=82, createdTime=2018-07-20, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e6f144e13a6, moduleTitle=JAMA Oncol：大血管侵犯的晚期肝细胞癌：TACE+RT vs索拉菲尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e6f144e13a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344631, encodeId=502313446310a, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=Lancet：乐伐替尼对比索拉菲尼治疗不可手术治疗的晚期肝细胞癌患者的效果对比, objectType=article, longId=129566, objectId=f407129566dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f407129566dd, replyNumber=0, likeNumber=76, createdTime=2018-02-12, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f407129566dd, moduleTitle=Lancet：乐伐替尼对比索拉菲尼治疗不可手术治疗的晚期肝细胞癌患者的效果对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f407129566dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344630, encodeId=faeb1344630df, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=J Hepatol：哪些因素会影响索拉菲尼治疗肝细胞癌的生存获益？, objectType=article, longId=122408, objectId=eb6412240877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb6412240877, replyNumber=0, likeNumber=72, createdTime=2017-12-07, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb6412240877, moduleTitle=J Hepatol：哪些因素会影响索拉菲尼治疗肝细胞癌的生存获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb6412240877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344629, encodeId=2432134462946, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=Lancet Oncol：局部晚期和不能手术的肝细胞癌——索拉菲尼vs钇-90内放射治疗, objectType=article, longId=117846, objectId=a85011e846a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a85011e846a9, replyNumber=0, likeNumber=0, createdTime=2017-10-29, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a85011e846a9, moduleTitle=Lancet Oncol：局部晚期和不能手术的肝细胞癌——索拉菲尼vs钇-90内放射治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a85011e846a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344628, encodeId=a069134462898, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=CLIN CANCER RES：TRC105联合索拉菲尼治疗肝细胞癌, objectType=article, longId=110762, objectId=6e82110e62aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e82110e62aa, replyNumber=0, likeNumber=83, createdTime=2017-08-26, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e82110e62aa, moduleTitle=CLIN CANCER RES：TRC105联合索拉菲尼治疗肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e82110e62aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344627, encodeId=4472134462ef2, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=Lancet Oncol：索拉菲尼+依维莫司联合用药治疗骨肉瘤未达到预期治疗效果, objectType=article, longId=45554, objectId=db84455542a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db84455542a, replyNumber=0, likeNumber=67, createdTime=2015-01-17, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db84455542a, moduleTitle=Lancet Oncol：索拉菲尼+依维莫司联合用药治疗骨肉瘤未达到预期治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db84455542a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344626, encodeId=65de134462630, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=PBC：索拉菲尼可降低神经母细胞瘤生长速度, objectType=article, longId=9621, objectId=c18c9621c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c18c9621c5, replyNumber=0, likeNumber=86, createdTime=2012-09-09, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c18c9621c5, moduleTitle=PBC：索拉菲尼可降低神经母细胞瘤生长速度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c18c9621c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344625, encodeId=841d134462591, content=<a href='/topic/show?id=af96e69750b' target=_blank style='color:#2F92EE;'>#索拉菲尼#</a>, objectTitle=索拉菲尼治疗晚期HCC控制率达到半数, objectType=article, longId=7485, objectId=61a0e4856c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61a0e4856c, replyNumber=0, likeNumber=71, createdTime=2012-06-30, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61a0e4856c, moduleTitle=索拉菲尼治疗晚期HCC控制率达到半数, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61a0e4856c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

索拉菲尼

2020-05-29

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

Lancet oncol：AML移植后采用索拉菲尼维持治疗的疗效和耐受性

2020-08-13

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

JITC：中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制

2020-05-04

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

J Immunother Cancer：营养与健康所等揭示中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制

2020-04-01

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

CLIN CANCER RES：索拉菲尼联合改良FOLFOX治疗晚期肝细胞癌

2019-01-22

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

JAMA Oncol：大血管侵犯的晚期肝细胞癌：TACE+RT vs索拉菲尼

2018-07-20

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

Lancet：乐伐替尼对比索拉菲尼治疗不可手术治疗的晚期肝细胞癌患者的效果对比

2018-02-12

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

J Hepatol：哪些因素会影响索拉菲尼治疗肝细胞癌的生存获益？

2017-12-07

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

Lancet Oncol：局部晚期和不能手术的肝细胞癌——索拉菲尼vs钇-90内放射治疗

2017-10-29

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

CLIN CANCER RES：TRC105联合索拉菲尼治疗肝细胞癌

2017-08-26

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

Lancet Oncol：索拉菲尼+依维莫司联合用药治疗骨肉瘤未达到预期治疗效果

2015-01-17

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

PBC：索拉菲尼可降低神经母细胞瘤生长速度

2012-09-09

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#索拉菲尼#

索拉菲尼治疗晚期HCC控制率达到半数

2012-06-30

科室
- - 订阅+
  - 更多科室
工具
服务